| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Cipriani Day Spa is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Calm - Apple`s 2017 iPhone App of the Year! Our mission is to make the world happier and healthier through the superpower of Calm.
Tufts Health Care Institute is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ABK Biomedical Inc. combines a compelling clinical market need with innovative biomaterials invented by Drs. Bob Abraham, Daniel Boyd and Sharon Kehoe.